JNJ-1900 (NBTXR3) demonstrated favorable safety and feasibility in a Phase 1 trial involving 22 patients with locally advanced or borderline resectable pancreatic cancer.
Nanobiotix has dosed the first patient in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3) for Stage 3 unresectable non-small cell lung cancer.
Nanobiotix transferred the US sponsorship of the Phase 3 NANORAY-312 head and neck cancer study to Janssen, a key step for NBTXR3 regulatory submission.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.